Dans la même rubrique
-
Partager cette page
David Vermijlen
Department of Pharmacotherapy and Pharmaceutics (DPP)
ContactRESEARCH ACTIVITIES
γδ T cells are unconventional T cells that express a γδ T cell receptor (TCR) on their cell surface instead of an αβ TCR as on conventional αβ T cells. γδ T cells can have several roles, including protection against infections and tumors. The general approach of our current research is to obtain insight into human γδ T cells by applying sophisticated molecular biological techniques on clinical samples. Important in vivo findings are then further investigated in vitro in order to understand molecular mechanisms. A main focus of our research is the role and ontogeny of human γδ T cells in early life. This research is leading to novel targets (molecules, cells) for pharmacotherapy.
Publications of David Vermijlen in PubMed :
David is also member of ULB's Center for Research in Immunology (U-CRI)
Selected publications
En attente des données.
Rafraîchir.
Career
- Since 2023: professor at the Department of Pharmacotherapy and Pharmaceutics, ULB
- Since 2022: WELBIO Investigator, WEL Research Institute
- 2012-2023: associate professor at the Department of Pharmacotherapy and Pharmaceutics, ULB
- 2006-2012: post-doctoral research fellow at the Institute for Medical Immunology, Université Libre de Bruxelles (ULB)
- 2003-2006: post-doctoral research fellow at the laboratory of Prof. Adrian Hayday at the Peter Gorer Department of Immunobiology, King’s College London, UK.
- 2003: Ph.D. thesis: “Tumor cell killing by hepatic natural killer cells”, at the VUB (Vrije Universiteit Brussel (VUB), Free University of Brussels)